Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: A randomized trial

被引:23
|
作者
Pieramico, O
Zanetti, MV
Innerhofer, M
Malfertheiner, P
机构
[1] UNIV MAGDEBURG,DEPT GASTROENTEROL HEPATOL & INFECT DIS,D-39106 MAGDEBURG,GERMANY
[2] OSPED GEN,DEPT MICROBIOL,I-39012 MERANO,ITALY
关键词
D O I
10.1111/j.1523-5378.1997.tb00065.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives, it was our goal to evaluate the efficacy and safety and patient compliance with omeprazole-based dual and triple therapy for eradication of Helicobacter pylori in peptic ulcer disease. Materials and Methods. One hundred seventy-five consecutive patients with H. pylori infection and associated active peptic ulcer were included. H. pylori infection was assessed by rapid urease test and histological analysis. Patients were randomized among three treatments: group 1 (56 patients): omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, for 2 weeks; group 2 (61 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and metronidazole, 500 mg bid, for 1 week; and group 3 (58 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and clarithromycin, 500 mg bid, for 1 week. Ulcer healing and cure of infection were evaluated at 4 to 6 weeks after cessation of therapy. Eradication rate was calculated per-protocol and by an intention-to-treat analysis. Results. At posttreatment endoscopy, duodenal ulcer was healed in 98.3% of patients. Eleven patients (6%) were lost to follow-up. H. pylori Infection was treated successfully in 55% (95% confidence interval [CI] = 41%-69%) of patients of group 1; 86% (95% CI = 77%-95%) of group 2 (p < .001 vs. group 1); and 93% (95% CI = 85%-100%) of group 3 (p < .001 vs. group I). On intention-to-treat analysis, eradication was 52%, 80%, and 86% in groups 1, 2, and 3, respectively. A good compliance was observed in more than 90% of patients of all groups. Side effects were reported by 7% of patients in group 1, 9% in group 2, and 11% in group 3. None of the patients stopped therapy because of side effects. Conclusions. Dual-therapy omeprazole-amoxicillin for 2 weeks is associated with significantly lower eradication rate than is 1-week omeprazole-based triple therapies. Triple therapy is well-tolerated and produces side effects similar to those of dual therapy. The highest cure rate of H. pylori infection was achieved with triple therapy of omeprazole, amoxicillin, and clarithromycin for 1 week.
引用
下载
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [21] A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: A prospective randomized 1-yr follow-up study
    Lerang, F
    Moum, B
    Ragnhildstveit, E
    Haug, JB
    Hauge, T
    Tolas, P
    Aubert, E
    Henriksen, M
    Efskind, PS
    Nicolaysen, K
    Soberg, T
    Odegaard, A
    Berge, T
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1997, 92 (04): : 653 - 658
  • [22] Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients
    Felga, Guilherme
    Silva, Fernando Marcuz
    Barbuti, Ricardo Correa
    Navarro-Rodriguez, Tomas
    Zaterka, Schlioma
    Eisig, Jaime Natan
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2010, 4 (11): : 712 - 716
  • [23] Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding
    Sheu, BS
    Chi, CH
    Huang, CC
    Kao, AW
    Wang, YL
    Yang, HB
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (01) : 137 - 143
  • [24] Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori
    Bunchorntavakul, Chalermrat
    Buranathawornsom, Arunluk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (12) : 3308 - 3313
  • [25] Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection:: a randomized, controlled trial in Vietnamese patients with duodenal ulcer
    Mao, HV
    Lak, BV
    Long, T
    Chung, NQ
    Thang, DM
    Hop, TV
    Chien, NN
    Hoan, PQ
    Henley, KS
    Perez-Perez, GI
    Connor, BA
    Stone, CD
    Chey, WD
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (01) : 97 - 101
  • [26] Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection:: results of a randomized controlled trial
    Kiyota, K
    Habu, Y
    Sugano, Y
    Inokuchi, H
    Mizuno, S
    Kimoto, K
    Kawai, K
    JOURNAL OF GASTROENTEROLOGY, 1999, 34 : 76 - 79
  • [27] Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: A randomized controlled trial
    Svoboda, P
    Kantorova, I
    Ochmann, J
    Doubek, J
    Kozumplik, L
    Marsova, J
    HEPATO-GASTROENTEROLOGY, 1997, 44 (15) : 886 - 890
  • [28] Triple Therapy Only for 7 Days Vs. Triple Therapy for 7 Days Plus Omeprazole for 21 Days in Treatment of Active Peptic Ulcer with Helicobacter Pylori Infection
    Oh, Hee Jung
    Shim, Ki-Nam
    Ryu, Kum-Hei
    Song, Ji-Hyun
    Song, Hyun-Joo
    Yeom, Hye-Jung
    Kim, Seong-Eun
    Kim, Tae-Hun
    Jung, Hye-Kyung
    Jung, Sung-Ae
    Yi, Sun-Young
    Yoo, Kwon
    Moon, Il-Hwan
    Chung, Kyu Won
    GASTROINTESTINAL ENDOSCOPY, 2006, 63 (05) : AB174 - AB174
  • [29] Helicobacter pylori infection and peptic ulcer disease in Uzbekistan
    Abdiev, Shavkat
    Ahn, Keun Soo
    Rahimov, Bakhodir
    Bahramov, Saidkarim
    Malikov, Yusuf R.
    Khadjibaev, Abduhakim M.
    Kurbanov, Fuat
    Hamajima, Nobuyuki
    HELICOBACTER, 2008, 13 (04) : 304 - 305
  • [30] Helicobacter pylori infection and peptic ulcer disease in cirrhosis
    Tsai, CJ
    DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (06) : 1219 - 1225